Quick Takeaways
- Invus Global Management, LLC filed SCHEDULE 13G/A for Syros Pharmaceuticals, Inc. Common Stock, $0.001 par value per share (SYRS).
- Disclosed ownership: 3.8%.
- Date of event: 31 Dec 2024.
Invus Global Management, LLC - 31 Dec 2024 SCHEDULE 13G/A Report for Syros Pharmaceuticals, Inc. Common Stock, $0.001 par value per share (SYRS)
- Filing Manager
- Invus Global Management, LLC
- Reporting Manager
- Invus Public Equities, L.P.
- Symbol
- SYRS
- Shares outstanding
- 27,995,500 shares
- Disclosed Ownership
- 1,063,829 shares
- Ownership
- 3.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Feb 2025, 16:30:02 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Invus Global Management, LLC disclosed 3.8% ownership in Syros Pharmaceuticals, Inc. Common Stock, $0.001 par value per share (SYRS) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Feb 2025, 16:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (8)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 3.8% | 1,063,829 | 1,063,829 | 0 | /s/ Raymond Debbane | Raymond Debbane, President, Invus Public Equities Advisors, LLC, its general partner | |
| Invus Public Equities Advisors, LLC | 3.8% | 1,063,829 | 1,063,829 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Invus Global Management, LLC | 3.8% | 1,063,829 | 1,063,829 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Siren, L.L.C. | 3.8% | 1,063,829 | 1,063,829 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Avicenna Life Sci Master Fund LP | 0% | 0 | 0 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer, Avicenna Life Sci Master GP LLC, its general partner | |
| Avicenna Life Sci Master GP LLC | 0% | 0 | 0 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer | |
| Ulys, L.L.C. | 0% | 0 | 0 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Raymond Debbane | 3.8% | 1,063,829 | 1,063,829 | 0 | /s/ Raymond Debbane | Raymond Debbane |